Bristol-Myers Hits 14-Year High On Cancer Drug Trial

By | January 12, 2015

Scalper1 News

Shares of Bristol-Myers Squibb (BMY) reached a 14-year high Monday after the pharma giant said a day earlier that a phase three trial of its drug Opdivo resulted in “superior overall survival” in the lung-cancer patients who took it. The results mark the first time a drug of Opdivo’s kind suggested a survival advantage in lung-cancer patients, the company said Sunday in a release. Shares rallied 4.4% on the stock market today to their highest Scalper1 News

Scalper1 News